Literature DB >> 27138789

Association between Circulating Vitamin D Metabolites and Fecal Bile Acid Concentrations.

Elizabeth T Jacobs1, Mark R Haussler2, David S Alberts3, Lindsay N Kohler4, Peter Lance4, María Elena Martínez5, Denise J Roe6, Peter W Jurutka7.   

Abstract

Although hydrophobic bile acids have been demonstrated to exhibit cytotoxic and carcinogenic effects in the colorectum, ursodeoxycholic acid (UDCA) has been investigated as a potential chemopreventive agent. Vitamin D has been shown to play a role in both bile acid metabolism and in the development of colorectal neoplasia. Using a cross-sectional design, we sought to determine whether baseline circulating concentrations of the vitamin D metabolites 25(OH)D and 1,25(OH)2D were associated with baseline fecal bile acid concentrations in a trial of UDCA for the prevention of colorectal adenoma recurrence. We also prospectively evaluated whether vitamin D metabolite concentrations modified the effect of UDCA on adenoma recurrence. After adjustment for age, sex, BMI, physical activity, and calcium intake, adequate concentrations of 25(OH)D (≥30 ng/mL) were statistically significantly associated with reduced odds for high levels of total [OR, 0.61; 95% confidence interval (CI), 0.38-0.97], and primary (OR, 0.61; 95% CI, 0.38-0.96) bile acids, as well as individually with chenodeoxycholic acid (OR, 0.39; 95% CI, 0.24-0.63) and cholic acid (OR, 0.56; 95% CI, 0.36-0.90). No significant associations were observed for 1,25(OH)2D and high versus low fecal bile acid concentrations. In addition, neither 25(OH)D nor 1,25(OH)2D modified the effect of UDCA on colorectal adenoma recurrence. In conclusion, this is the first study to demonstrate an inverse relationship between circulating levels of 25(OH)D and primary fecal bile acid concentrations. These results support prior data demonstrating that vitamin D plays a key role in bile acid metabolism, and suggest a potential mechanism of action for 25(OH)D in colorectal cancer prevention. Cancer Prev Res; 9(7); 589-97. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27138789      PMCID: PMC4993194          DOI: 10.1158/1940-6207.CAPR-16-0033

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  40 in total

Review 1.  Assessment of circulating 25(OH)D and 1,25(OH)2D: emergence as clinically important diagnostic tools.

Authors:  Bruce W Hollis
Journal:  Nutr Rev       Date:  2007-08       Impact factor: 7.110

2.  Risk modification of colorectal adenoma by CYP7A1 polymorphisms and the role of bile acid metabolism in carcinogenesis.

Authors:  Betsy C Wertheim; Jeffrey W Smith; Changming Fang; David S Alberts; Peter Lance; Patricia A Thompson
Journal:  Cancer Prev Res (Phila)       Date:  2011-11-04

3.  Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence.

Authors:  David S Alberts; María Elena Martínez; Lisa M Hess; Janine G Einspahr; Sylvan B Green; A K Bhattacharyya; Jose Guillen; Mary Krutzsch; Ashok K Batta; Gerald Salen; Liane Fales; Kris Koonce; Dianne Parish; Mary Clouser; Denise Roe; Peter Lance
Journal:  J Natl Cancer Inst       Date:  2005-06-01       Impact factor: 13.506

Review 4.  Bile acids in the colon, from healthy to cytotoxic molecules.

Authors:  Juan I Barrasa; Nieves Olmo; Ma Antonia Lizarbe; Javier Turnay
Journal:  Toxicol In Vitro       Date:  2012-12-27       Impact factor: 3.500

5.  Chemoprevention of colorectal cancer with ursodeoxycholic acid: cons.

Authors:  Elizabeth J Carey; Keith D Lindor
Journal:  Clin Res Hepatol Gastroenterol       Date:  2012-09       Impact factor: 2.947

6.  Molecular and functional comparison of 1,25-dihydroxyvitamin D(3) and the novel vitamin D receptor ligand, lithocholic acid, in activating transcription of cytochrome P450 3A4.

Authors:  Peter W Jurutka; Paul D Thompson; G Kerr Whitfield; Kristina R Eichhorst; Neal Hall; Carlos Encinas Dominguez; Jui-Cheng Hsieh; Carol A Haussler; Mark R Haussler
Journal:  J Cell Biochem       Date:  2005-04-01       Impact factor: 4.429

7.  Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study.

Authors:  Lawrence Serfaty; Antoine De Leusse; Olivier Rosmorduc; Benoit Desaint; Jean-Francois Flejou; Olivier Chazouilleres; Renée E Poupon; Raoul Poupon
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

Review 8.  High prevalence of vitamin D inadequacy and implications for health.

Authors:  Michael F Holick
Journal:  Mayo Clin Proc       Date:  2006-03       Impact factor: 7.616

9.  Circulating fibroblast growth factor-23 is associated with increased risk for metachronous colorectal adenoma.

Authors:  Elizabeth Jacobs; Maria Elena Martinez; Julie Buckmeier; Peter Lance; Melissa May; Peter Jurutka
Journal:  J Carcinog       Date:  2011-02-12

10.  Association between fecal bile acids and colorectal cancer: a meta-analysis of observational studies.

Authors:  Jin Lu Tong; Zhi Hua Ran; Jun Shen; Guo Quan Fan; Shu Dong Xiao
Journal:  Yonsei Med J       Date:  2008-10-31       Impact factor: 2.759

View more
  3 in total

1.  Serum 25-hydroxyvitamin D concentrations in dogs with gallbladder mucocele.

Authors:  Jared A Jaffey; Jodi Matheson; Kate Shumway; Christina Pacholec; Tarini Ullal; Lindsay Van den Bossche; Hille Fieten; Randy Ringold; Keun Jung Lee; Amy E DeClue
Journal:  PLoS One       Date:  2020-12-16       Impact factor: 3.240

2.  The Association of Serum Total Bile Acids With Bone Mineral Density in Chinese Adults Aged 20-59: A Retrospective Cross-Sectional Study.

Authors:  Jingxin Liu; Yuxing Chen; Qi Luo
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-19       Impact factor: 6.055

3.  Vitamin D intake as well as circulating 25-hydroxyvitamin D level and risk for the incidence and recurrence of colorectal cancer precursors: A meta-analysis.

Authors:  Li-Liangzi Guo; Si-Si Chen; Li-Xian Zhong; Kai-Yin He; Yu-Ting Li; Wei-Wei Chen; Qiu-Ting Zeng; Shao-Hui Tang
Journal:  Front Med (Lausanne)       Date:  2022-08-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.